Skip to content

Atezolizumab PK: baseline patient profiles

Compare circulating atezolizumab exposure under fixed patient covariates and constant clearance. The released two-compartment model includes intravenous infusions and cumulative exposure.

Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL ↗

JTO Clinical and Research Reports

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do the declared sex and ADA contexts change atezolizumab exposure?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Two 1200 mg q3w infusions at fixed reference covariates

Fixed circulating-PK example with supplied covariates, individual coordinates and explicit central mg infusions; no original patient or cohort reconstruction.

0–42 day

Scenario details

Two 1200 mg q3w infusions at fixed reference covariates

Fixed circulating-PK example with supplied covariates, individual coordinates and explicit central mg infusions; no original patient or cohort reconstruction.

Readouts

Concentration · ug/mL
Named conditional PK state, observer or diagnostic; units as declared.
Exposure (AUC) · ug*day/mL
Named conditional PK state, observer or diagnostic; units as declared.
Eliminated · mg
Named conditional PK state, observer or diagnostic; units as declared.
Accounted drug · mg
Named conditional PK state, observer or diagnostic; units as declared.

Study purpose

  • How do the model's key biological readouts change under two 1200 mg q3w infusions at fixed reference covariates?

Assumptions

  • Interpret patterns within this model and starting configuration; do not treat them as clinical predictions or treatment recommendations.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
42 → 168

Time between reported samples.

day
0.02083 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

Initial constant-clearance two-compartment atezolizumab disposition under fixed covariates, with explicit central infusions, cumulative exposure and physical drug accounting.

Initial constant-clearance two-compartment atezolizumab disposition under fixed covariates, with explicit central infusions, cumulative exposure and physical drug accounting.

Model details

25 parameters · 5 states · 5 equations · 20 derived outputs

Classification & API access
Therapeutic
Atezolizumab
Modality
Monoclonal antibody
Target
PD-L1 / CD274
Disease / scope
Advanced or recurrent non-small cell lung cancer
ParameterDefaultUnitDescription
Population systemic clearanceCL_pop_L_day0.2L/dayPopulation systemic clearance governing removal of modeled material from the relevant compartment.
Population intercompartmental clearanceQ_pop_L_day0.546L/dayPopulation intercompartmental clearance governing exchange between model compartments.
Population central distribution volumeV1_pop_L3.28LPopulation central distribution volume used to convert modeled amount to concentration in the relevant compartment.
Population peripheral distribution volumeV2_pop_L3.63LPopulation peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.
Serum albuminalbumin_g_L39g/LSerum albumin used by this model.
Albumin reference galbumin_reference_g_L40g/LAlbumin reference g coefficient used by the released system of model equations.
Atag positiveatag_positive0—Atag positive coefficient used by the released system of model equations.
Body weightbody_weight_kg58.6kgBody weight used for body-size scaling in the model.
Body weight referencebody_weight_reference_kg77kgBody weight reference used for body-size scaling in the model.
Eta clearanceeta_cl0—Eta clearance governing removal of modeled material from the relevant compartment.
Eta distribution volume 1eta_v10—Eta distribution volume 1 used to convert modeled amount to concentration in the relevant compartment.
Eta distribution volume 2eta_v20—Eta distribution volume 2 used to convert modeled amount to concentration in the relevant compartment.
Source additive residual variancefda_residual_additive_variance_ug_ml216.6µg²/mL²FDA Table6 sigma-squared value; no observation noise or likelihood is generated.
Source proportional residual variancefda_residual_proportional_variance0.0433—FDA Table6 sigma-squared value; used only for a named observation-SD diagnostic, no noise draw.
Femalefemale0—Female coefficient used by the released system of model equations.
Typical albumin clearancetheta_albumin_CL-1.12—Typical albumin clearance governing removal of modeled material from the relevant compartment.
Typical albumin distribution volume 1theta_albumin_V1-0.35—Typical albumin distribution volume 1 used to convert modeled amount to concentration in the relevant compartment.
Typical atag clearancetheta_atag_CL0.159—Typical atag clearance governing removal of modeled material from the relevant compartment.
Typical body weight clearancetheta_body_weight_CL0.808—Typical body weight clearance used for body-size scaling in the model.
Typical body weight distribution volume 1theta_body_weight_V10.559—Typical body weight distribution volume 1 used for body-size scaling in the model.
Typical female distribution volume 1theta_female_V1-0.129—Typical female distribution volume 1 used to convert modeled amount to concentration in the relevant compartment.
Typical female distribution volume 2theta_female_V2-0.272—Typical female distribution volume 2 used to convert modeled amount to concentration in the relevant compartment.
Typical tumor burden clearancetheta_tumor_burden_CL0.125—Typical tumor burden clearance governing removal of modeled material from the relevant compartment.
Tumor burden mmtumor_burden_mm43.9mmTumor burden mm coefficient used by the released system of model equations.
Tumor burden reference mmtumor_burden_reference_mm63mmTumor burden reference mm coefficient used by the released system of model equations.

Related models

Atezolizumab PK: standard and loading schedulesAtezolizumab exposure across pediatric and young-adult cohortsEnvafolimab subcutaneous population PKDupilumab exposure and atopic-dermatitis response

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics